Summary
The pharmacokinetics of a new, potent H2-receptor antagonist, famotidine, 20 mg i.v. was studied in 7 subjects with normal renal function and in 24 patients with varying degrees of renal impairment. The volume of distribution at steady state was 1.14 l/kg in normal subjects and was not altered in renal failure. The half-life of elimination was 2.59 h in normal subjects and was unchanged in mild renal failure (creatinine clearance, CLCR 90–60 ml/min/1.48 m2) but was increased to 4.72 h in moderate renal failure (CLCR 60–30 ml/min/1.48 m2), and to 12.07 h in severe renal failure (CLCR below 30 ml/min/1.48 m2). The cumulative urinary excretion and renal clearance of famotidine were correspondingly reduced in patients with impaired kidney function. In normal subjects and in patients with mild to moderate renal failure, about 70% of famotidine was excreted through the kidney, mainly by tubular secretion. In patients with a CLCR above 60 ml/min/1.48 m2 the normal daily dose of famotidine can be employed, but in those with a CLCR between 60 and 30 ml/min/1.48 m2 the dose should be reduced by half, and in patients with a CLCR below 30 ml/min/1.48 m2 a reduction by three quarters of the normal dose is recommended.
Similar content being viewed by others
References
Takagi T, Takada M, Maeno H (1982) Effect of a new potent H2-blocker, 3-[[[ 2-[(diaminomethylene)amino]-4-thiazolyl] methyl]-thio]-N2sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs. Arch Int Pharmacodyn Ther 256: 49–58
Miwa M, Tani N, Miwa T (1984) Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects. Int J Clin Pharmacol Ther Toxicol 22: 214–217
Kawai R, Yamada S, Kawamura S, Miwa T, Miwa M (1984) Pharmacokinetics of famotidine (YM-11170), a new histamine H2-receptor antagonist. Part 2: Absorption and excretion in dogs and humans. Ohyo Yakuri (Pharmacometrics) 27 [1]: 73–77
Ventkateswaran PS, Jeffers A, Hocken AG (1972) Gastric acid secretion in chronic renal failure. Br Med J 4: 22–23
Shepherd AMM, Stewart WK, Wormsley KG (1973) Peptic ulceration in chronic renal failure. Lancet 1: 1357–1359
Doherty CC, O'Connor FA, Buchanan KD, McGeown MG (1977) Cimetidine for duodenal ulceration in patients undergoing haemodialysis. Br Med J 2: 1506–1508
Jones RH, Levin MR, Parsons V (1979) therapeutic effect of cimetidine in patients undergoing haemodialysis. Br Med J 1: 650–652
Metzler CM, Elfring GK, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 130: 562–563
Gibald M, Perrier D (1975) Pharmacokinetics. In: Swarbrick J (ed) Drugs and pharmaceutical sciences, vol 1. Marcel Dekker, New York, pp 45–96
Walkenstein SS, Dubb JW, Randolph WC, Westlake WJ, Stote RM, Intoccia AP (1978) Bioavailability of cimetidine in man. Gastroenterology 74: 360–365
Ma KW, Brown DC, Masler DS, Silvis SE (1978) Effects of renal failure on blood levels of cimetidine. Gastroenterology 74: 473–477
Krichman KH, Cutler RE, Blair AD (1979) Pharmacokinetics of cimetidine and uremic humans. Clin Res 27: 1, 73A
Dettli L (1977) Elimination kinetics and dosage adjustment of drugs in patients with kidney disease. Prog Pharmacol 1: 17–23
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takabatake, T., Ohta, H., Maekawa, M. et al. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol 28, 327–331 (1985). https://doi.org/10.1007/BF00543332
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543332